

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**撥康視云™**

Cloudbreak Pharma

**CLOUDBREAK PHARMA INC.**

**撥康視雲製藥有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2592)**

## **DATE OF BOARD MEETING**

The board (the “**Board**”) of directors (the “**Directors**”) of Cloudbreak Pharma Inc. (the “**Company**”; together with its subsidiaries, the “**Group**”) hereby announces that a meeting of the Board will be held on Monday, 31 August 2026 for the purposes of, among other matters, considering and approving the unaudited interim results of the Group for the six months ended 30 June 2026 for publication and the recommendation of the payment of an interim dividend, if any.

By order of the Board  
**Cloudbreak Pharma Inc.**

**Dr. NI Jinsong**

*Chairman, Executive Director and Chief Executive Officer*

Hong Kong, 19 August 2026

*As at the date of this announcement, the Board comprises: (i) Dr. Ni Jinsong, Mr. Dinh Son Van and Dr. Yang Rong as executive Directors; (ii) Dr. Li Jun Zhi, Mr. Cao Xu and Mr. Xia Zhidong as non-executive Directors; and (iii) Ms. Nie Sijiang, Mr. Ma Yiu Ho Peter and Mr. Lee Alex Jao Jang as independent non-executive Directors.*

\* For identification purposes only